Centers of Excellence
Advanced Prostate Cancer
From the Editor
Tackling Hard Problems is Not Soft Science
For nearly the past decade, I have studied complications of cancer survivorship and how patients might better integrate this information into their treatment decisions. Most of this has centered on complications of hormonal therapy for men with prostate cancer, with an emphasis on assessing complications from the patient prospective using patient reported outcome measures, in addition to objective scientific measures like the CTCAE.
Alicia Morgans, MD, MPH
Alicia Morgans, MD, MPH is the Assistant Professor of medicine in the Division of Hematology/Oncology at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. She specializes in the treatment of genitourinary malignancies, including cancers of the prostate, bladder and testis (germ cell) and penis. Dr. Morgans’ research focus is on complications of prostate cancer survivorship and treatment decision making in advanced prostate cancer.
ASCO 2017 Prostate Cancer
- ASCO 2017: Next-generation sequencing of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer June 5, 2017
- ASCO 2017: Making Androgen Receptor Targeted Therapy Great Again June 3, 2017
EAU 2016 - Prostate Cancer
- Many vs. Cancer: First Major Global Crowd funding Effort to Defeat Prostate Cancer
- A Look at the Prostate Cancer Foundation Its History and Contributions to Medical Progress: Interview with Stuart Holden
- Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
- The PRONOUNCE Trial for patients with advanced prostate cancer and cardiovascular disease receiving degarelix or leuprolide.
- Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry.